About Wren Capital
Wren Capital is a venture capital firm founded in 2011. It is primarily based out of London, United Kingdom. As of Dec 2025, Wren Capital is an active investor, having invested in 37 companies, with 2 new investments in the last 12 months. It primarily invests in Seed round in United Kingdom based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Seed round of HotHouse Therapeutics Overall, Wren Capital portfolio has seen 4 acquisitions, namely Horizon Discovery and Arachnys. A lot of funds co-invest with Wren Capital, with names like ACF Investors sharing a substantial percentage of its portfolio. Wren Capital has team of 2 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed, Series A & 4 more
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Wren Capital's List of Top Investments
Wren Capital has a portfolio of 37 companies. Their most notable investments are in Exonate and Antiverse.Their portfolio spans across United Kingdom and Portugal. They have invested in Life Sciences, High Tech, Enterprise Applications and 15 other sectors, across stages such as Seed, Series A and 4 more. Here is the list of top investments by Wren Capital:
Developer of cell lines with genetic modification using AAV gene-editing platform. The company has cell line engineering, knockout cell lines, and reporter cell lines. It also provides services in T cell activation assay, lymphocyte reaction assay, T cell-mediated tumor cell lysis assay, ADCC, and CDC assays, gene-editing for immuno-oncology, CRISPR Screening, drug combination screening, in vitro assay, and in-vivo assay.
Key facts about Horizon Discovery
- Founded Year: 2007
- Location: Cambridge (United Kingdom)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $46.3M
- Employee Count: 94 as on Apr 30, 2026
- Investors: ValueAct Capital, Draper Esprit and 13 Others
- Latest Funding Round: Post IPO, Sep 07, 2018, $*****
- Highlight: Acquired
2. Antiverse
Developer of computational platform for de novo design of antibody therapeutics. The platform combines machine learning techniques and cell line engineering for challenging targets. It facilitates design for drug targets, including G-protein coupled receptors and ion channels. The technology enables movement from target identification to functional antibody.
Key facts about Antiverse
- Founded Year: 2017
- Location: Cardiff (United Kingdom)
- Stage: Series A
- Total Funding till date: $20M
- Employee Count: 15 as on Apr 30, 2025
- Investors: Cambridge Angels, ACF Investors and 34 Others
- Latest Funding Round: Series A, Mar 03, 2026, $*****
- Highlight: Editors' Pick
Manufacturer of deployable antenna systems for space-based satellite services. It offers a portfolio of antennas focused on maximizing stowage efficiency and improving performance. Products include helical, Yagi, wrapped rib, offset reflectors, and hinged rib antennas. It provides solutions for future space-based services.
Key facts about Oxford Space Systems
- Founded Year: 2013
- Location: Harwell (United Kingdom)
- Annual Revenue: £1M - £10M as on Dec 31, 2024
- Valuation: $*****
- Stage: Series A
- Total Funding till date: $31M
- Employee Count: 97 as on May 31, 2026
- Investors: Foresight Group, Cambridge Angels and 36 Others
- Latest Funding Round: Grant (prize money), Jan 08, 2024, $*****
- Highlight: Editors' Pick
Developer of new treatments to restore healthy mitochondrial metabolism in patients. The company's small molecule asset, MTRX31, targets the elimination of ectopic fat from affected organs, in people with metabolically unhealthy obesity, by resetting mitochondrial function rather than suppressing appetite.
Key facts about MitoRx Therapeutics
- Founded Year: 2021
- Location: Harwell (United Kingdom)
- Stage: Seed
- Total Funding till date: $12.2M
- Employee Count: 13 as on May 31, 2026
- Investors: Longevitytech.fund, Wren Capital and 21 Others
- Latest Funding Round: Seed, Nov 17, 2025, $*****
- Highlight: Editors' Pick
5. Spotta
Smart insect monitoring as a service for sustainable pest management. It offers cutting-edge, real-time monitoring solutions for various industries impacted by insect pests. The company utilizes IoT-enabled pods and advanced algorithms to detect and alert users to pest infestations before significant damage occurs. This proactive approach enables timely intervention, reducing the need for extensive pesticide use and minimizing economic losses. The service provides solutions for bed bug monitoring, pine weevil detection, and date palm management, with the flexibility to adapt to other insect-related challenges. It is a B2B SaaS company that delivers data-driven insights, empowering businesses to make informed decisions and implement sustainable pest control strategies. The company's mission is to revolutionize insect pest management through technology, promoting environmental sustainability and cost-effectiveness.
Key facts about Spotta
- Founded Year: 2018
- Location: Cambridge (United Kingdom)
- Stage: Series B
- Total Funding till date: $9.55M
- Employee Count: 29 as on May 31, 2026
- Investors: Cambridge Angels, Cambridge Capital Group and 10 Others
- Latest Funding Round: Series B, Oct 06, 2025, $*****
Wren Capital's Year-on-Year Investment Trends
Wren Capital has invested in 37 companies over the last 14 years, with an average of 1 new investment annually in the last 10 years. In 2025, it made 3 investments. Its most recent first time investment was in HotHouse Therapeutics and most recent follow-on round was in Monument Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 2 | 1 | 3 |
2024 | 0 | 0 | 0 |
2023 | 0 | 2 | 2 |
2022 | 1 | 2 | 3 |
2021 | 3 | 0 | 3 |
2020 | 2 | 0 | 2 |
2019 | 0 | 1 | 1 |
2018 | 2 | 1 | 3 |
2017 | 1 | 0 | 1 |
Wren Capital's Investments by Stage
Wren Capital has made 14 investments in Seed stage with an average round size of $2.12M, 7 investments in Series A stage with an average round size of $5.9M and 1 investment in Angel stage with an average round size of $2.9M.Stage of entry | No. of Investments |
|---|---|
Seed | 14 |
Series A | 7 |
Angel | 1 |
PE | 1 |
Series B | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Wren Capital's Investments by Sector
Wren Capital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, HealthTech and Sustainability Tech. Notably, it has invested in 35 Tech companies, 32 Enterprise (B2B) companies, 13 Tech hardware companies and at least 10 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 16 |
High Tech | 13 |
Enterprise Applications | 5 |
HealthTech | 5 |
Sustainability Tech | 5 |
Others | 18 |
Note: We have considered here, only first round of investments
Wren Capital's Investments by Geography
Wren Capital has made most investments in United Kingdom (24), followed by Portugal where it has made 1 investment.Country | No. of Investments |
|---|---|
United Kingdom | 24 |
Portugal | 1 |
Note: We have considered here, only first round of investments
Wren Capital's recent investments
Wren Capital has not made any investment in 2026 so far.Here are the most recent investments by Wren Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Dec 02, 2025 | United Kingdom | Seed | 4492 | [+3] | |
Sep 08, 2025 | United Kingdom | Seed | 9266 | ||
Feb 25, 2025 | United Kingdom | Seed | 7185 | [+1] | |
Dec 15, 2023 | United Kingdom | Series A | 2543 | [+6] | |
Dec 13, 2023 | United Kingdom | Seed | 1560 |
Acquired companies in Wren Capital's Portfolio
4 companies from Wren Capital's portfolio have been acquired. The most recent acquisition was Arachnys in Mar 2021 by AML RightSource for $*****.Here are Wren Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 09, 2021 | - | - | 8165 | |
Nov 02, 2020 | Jun 03, 2013 | Series C | 6420 | |
Dec 12, 2019 | Mar 21, 2016 | Seed | 1767 | |
Mar 13, 2017 | Jan 30, 2015 | Series A | 6220 |
Team profile of Wren Capital
Wren Capital has a team of 2 members including 2 Partners located in United Kingdom. Wren Capital's team does not sit on the board of any company as of now.Co-investors of Wren Capital
Over the past 14 years, 181 investors have co-invested in Wren Capital's portfolio companies. This includes funds and angels.
- Invested before Wren Capital: UK Innovation Science & Seed Fund, Finance Wales and 41 others have invested in rounds before Wren Capital. There are 4 companies where UK Innovation Science & Seed Fund has invested before Wren Capital and 3 companies where Finance Wales has invested before Wren Capital.
- Top Co-investors of Wren Capital: 54 investors entered a company along with Wren Capital. These include investors like ACF Investors (5 companies).
- Invested after Wren Capital: A total of 84 investors have invested in Wren Capital's portfolio after their investments. Top Investors include UK Innovation Science & Seed Fund (3 companies), CARB-X (2 companies) and Maven Capital Partners (2 companies).
Recent News related to Wren Capital
•
HotHouse Therapeutic secures £2.9 million Pre-Seed Investment from investors including SynBioVenUK Tech Investment News•Dec 02, 2025•HotHouse Therapeutics, Twin Path Ventures, SynBioVen, Wren Capital and 2 others
•
•
Spotta Raises £3M in FundingFinSMEs•Dec 15, 2023•Spotta, The Yield Lab, STIHL Ventures, ACF Investors and 6 others
•
MitoRx Therapeutics Closes Seed Extension FinancingFinSMEs•Dec 14, 2023•MitoRx Therapeutics, UK Innovation Science & Seed Fund, Wren Capital, Longevitytech.fund and 2 others
•
•
•
Adapttech Raises £2.25M in FundingFinSMEs•Apr 06, 2022•Adapttech, Midlands Engine Investment Fund, Mercia, ACF Investors and 2 others
•
Centauri Therapeutics’ $32 Million Series A InvestmentGlobal Legal Chronicle•Feb 19, 2022•Centauri Therapeutics, Boehringer Ingelheim Venture Fund, Evotec, REPAIR Impact Fund and 2 others
•
Biomedical startup Adapttech lands £2 million funding roundAngel News•Mar 26, 2021•Adapttech, Midlands Engine Investment Fund, Bionova Capital, ACF Investors and 2 others
•
Development Bank Invests in AI Antibody Drug Discovery PlatformBusiness News Wales•Mar 23, 2021•Antiverse, Development Bank of Wales, Tensor Ventures, Wren Capital and 2 others
